JP2021525770A5 - - Google Patents
Info
- Publication number
- JP2021525770A5 JP2021525770A5 JP2020567109A JP2020567109A JP2021525770A5 JP 2021525770 A5 JP2021525770 A5 JP 2021525770A5 JP 2020567109 A JP2020567109 A JP 2020567109A JP 2020567109 A JP2020567109 A JP 2020567109A JP 2021525770 A5 JP2021525770 A5 JP 2021525770A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- cancer
- cancer treatment
- signature sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023116746A JP2023134704A (ja) | 2018-05-28 | 2023-07-18 | がんの治療での使用のためのｃｃｒ５阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677114P | 2018-05-28 | 2018-05-28 | |
| US62/677,114 | 2018-05-28 | ||
| US201962792600P | 2019-01-15 | 2019-01-15 | |
| US62/792,600 | 2019-01-15 | ||
| PCT/IB2019/054350 WO2019229616A1 (en) | 2018-05-28 | 2019-05-24 | Ccr5 inhibitor for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116746A Division JP2023134704A (ja) | 2018-05-28 | 2023-07-18 | がんの治療での使用のためのｃｃｒ５阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525770A JP2021525770A (ja) | 2021-09-27 |
| JP2021525770A5 true JP2021525770A5 (enExample) | 2022-05-23 |
| JP7319020B2 JP7319020B2 (ja) | 2023-08-01 |
Family
ID=67480241
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567109A Active JP7319020B2 (ja) | 2018-05-28 | 2019-05-24 | がんの治療での使用のためのｃｃｒ５阻害剤 |
| JP2023116746A Pending JP2023134704A (ja) | 2018-05-28 | 2023-07-18 | がんの治療での使用のためのｃｃｒ５阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116746A Pending JP2023134704A (ja) | 2018-05-28 | 2023-07-18 | がんの治療での使用のためのｃｃｒ５阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210205411A1 (enExample) |
| EP (1) | EP3813870B1 (enExample) |
| JP (2) | JP7319020B2 (enExample) |
| KR (1) | KR20210016398A (enExample) |
| CN (1) | CN112469429B (enExample) |
| AU (1) | AU2019276939A1 (enExample) |
| BR (1) | BR112020024328A2 (enExample) |
| CA (1) | CA3101556A1 (enExample) |
| MX (1) | MX2020012782A (enExample) |
| WO (1) | WO2019229616A1 (enExample) |
| ZA (1) | ZA202007955B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114729023A (zh) * | 2019-04-01 | 2022-07-08 | 西托戴恩股份有限公司 | 阻断癌症转移或增强由dna损伤化学疗法诱导的细胞死亡的抗ccr5药剂和治疗方法 |
| WO2021231648A2 (en) * | 2020-05-12 | 2021-11-18 | Gigagen, Inc. | Cancer therapeutics comprising chemokine or its analog |
| WO2024146707A1 (en) * | 2023-01-06 | 2024-07-11 | Université De Genève | Variant ligand conjugates for payload delivery |
| WO2025172252A1 (en) | 2024-02-15 | 2025-08-21 | Novo Nordisk A/S | Protracted ccr5 antagonists and uses thereof |
| WO2025176787A1 (en) * | 2024-02-22 | 2025-08-28 | Orion Biotechnology Holding Sa | Ccl5 variants for modulating gpr75 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0614755D0 (en) * | 2006-07-25 | 2006-09-06 | Univ Geneve | Cytokine derivatives |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8916696B2 (en) * | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
| EP3693041A1 (en) * | 2011-06-13 | 2020-08-12 | TLA Targeted Immunotherapies AB | Treating cancer |
| HK1209673A1 (en) * | 2012-05-14 | 2016-04-08 | Prostagene Llc | Using modulators of ccr5 for treating cancer |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| US20180289689A1 (en) * | 2014-10-27 | 2018-10-11 | Ruprecht-Karls-Universität Heidelberg | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer |
| AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
-
2019
- 2019-05-24 AU AU2019276939A patent/AU2019276939A1/en not_active Abandoned
- 2019-05-24 BR BR112020024328-0A patent/BR112020024328A2/pt not_active IP Right Cessation
- 2019-05-24 KR KR1020207037076A patent/KR20210016398A/ko not_active Withdrawn
- 2019-05-24 WO PCT/IB2019/054350 patent/WO2019229616A1/en not_active Ceased
- 2019-05-24 MX MX2020012782A patent/MX2020012782A/es unknown
- 2019-05-24 CA CA3101556A patent/CA3101556A1/en active Pending
- 2019-05-24 EP EP19746141.1A patent/EP3813870B1/en active Active
- 2019-05-24 JP JP2020567109A patent/JP7319020B2/ja active Active
- 2019-05-24 CN CN201980047951.5A patent/CN112469429B/zh active Active
- 2019-05-24 US US17/057,579 patent/US20210205411A1/en not_active Abandoned
-
2020
- 2020-12-18 ZA ZA2020/07955A patent/ZA202007955B/en unknown
-
2023
- 2023-07-18 JP JP2023116746A patent/JP2023134704A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prud'homme et al. | Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity | |
| Okroj et al. | Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors | |
| CA2443617A1 (en) | Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions | |
| JP2017006120A5 (enExample) | ||
| Sgouras et al. | Activity and functional importance of Helicobacter pylori virulence factors | |
| CY1109463T1 (el) | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν | |
| JP2013509861A5 (enExample) | ||
| EP2185197A4 (en) | NEW CELL FACTORY SOLUTION COMPOSITIONS | |
| EP3927734A1 (en) | Hypoxia-responsive chimeric antigen receptors | |
| MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
| Okamoto et al. | Emerging roles of a chemoattractant receptor GPR15 and ligands in pathophysiology | |
| Gu et al. | Identification and characterization of pro-interleukin-16 from mud crab Scylla paramamosain: the first evidence of proinflammatory cytokine in crab species | |
| Ahmed et al. | Tumor stroma as a target in cancer | |
| Yoon et al. | The role of gastrokine 1 in gastric cancer | |
| Tan et al. | Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities | |
| Jonckheere et al. | Transcriptional activation of the murine Muc5ac mucin gene in epithelial cancer cells by TGF-beta/Smad4 signalling pathway is potentiated by Sp1 | |
| Qin et al. | PARP1 interacts with WDR5 to enhance target gene recognition and facilitate tumorigenesis | |
| JP2018527926A5 (enExample) | ||
| JP2006158399A5 (ja) | 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤 | |
| JP2007536891A5 (enExample) | ||
| JP4719670B2 (ja) | Ｎ−ｍｙｃ発現腫瘍におけるヒトＮ−ｍｙｃ遺伝子のアンチセンスおよびアンチジーンペプチド核酸（ＰＮＡ）による選択的阻害法 | |
| JP2007511534A5 (enExample) | ||
| RU2006119452A (ru) | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение | |
| AU2022221660B2 (en) | Multi-domain fusion protein and use thereof | |
| CN103534273B (zh) | 环化变构trail/apo2l及其编码基因与应用 |